Concepts (227)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Heart-Assist Devices | 19 | 2024 | 991 | 2.430 |
Why?
|
| Shock, Cardiogenic | 4 | 2026 | 174 | 2.240 |
Why?
|
| Heart Failure | 25 | 2025 | 2306 | 1.980 |
Why?
|
| Ventricular Function, Left | 10 | 2020 | 547 | 1.420 |
Why?
|
| Myocardium | 9 | 2019 | 874 | 1.320 |
Why?
|
| Heart Ventricles | 9 | 2018 | 769 | 1.010 |
Why?
|
| Myocardial Ischemia | 6 | 2019 | 310 | 0.960 |
Why?
|
| Cytokines | 2 | 2021 | 1346 | 0.890 |
Why?
|
| Cardiomyopathies | 5 | 2019 | 514 | 0.890 |
Why?
|
| Proteome | 2 | 2024 | 286 | 0.860 |
Why?
|
| Recovery of Function | 5 | 2017 | 456 | 0.830 |
Why?
|
| Inflammation Mediators | 1 | 2024 | 226 | 0.760 |
Why?
|
| Biomarkers | 5 | 2024 | 3403 | 0.690 |
Why?
|
| Hemodynamics | 4 | 2024 | 816 | 0.680 |
Why?
|
| Oxygenators, Membrane | 1 | 2020 | 3 | 0.680 |
Why?
|
| Proteomics | 1 | 2024 | 606 | 0.620 |
Why?
|
| Inflammation | 3 | 2024 | 1490 | 0.610 |
Why?
|
| Lymphocytes | 1 | 2020 | 359 | 0.580 |
Why?
|
| Neutrophils | 1 | 2020 | 372 | 0.560 |
Why?
|
| Myocardial Reperfusion Injury | 2 | 2015 | 127 | 0.510 |
Why?
|
| Extracorporeal Membrane Oxygenation | 1 | 2024 | 676 | 0.510 |
Why?
|
| Ventricular Remodeling | 4 | 2020 | 155 | 0.450 |
Why?
|
| Diastole | 2 | 2015 | 179 | 0.450 |
Why?
|
| Ventricular Dysfunction, Left | 2 | 2015 | 359 | 0.440 |
Why?
|
| Coronary Circulation | 4 | 2015 | 190 | 0.330 |
Why?
|
| Machine Learning | 2 | 2025 | 375 | 0.300 |
Why?
|
| Middle Aged | 24 | 2026 | 28839 | 0.300 |
Why?
|
| Time Factors | 9 | 2024 | 6273 | 0.290 |
Why?
|
| Myocardial Infarction | 3 | 2026 | 998 | 0.270 |
Why?
|
| Myocardial Contraction | 4 | 2017 | 248 | 0.260 |
Why?
|
| Pulmonary Wedge Pressure | 2 | 2025 | 47 | 0.250 |
Why?
|
| RNA | 2 | 2023 | 531 | 0.240 |
Why?
|
| Heart Transplantation | 3 | 2021 | 832 | 0.230 |
Why?
|
| Male | 26 | 2026 | 65158 | 0.230 |
Why?
|
| Mitochondria, Heart | 2 | 2016 | 51 | 0.230 |
Why?
|
| Aged | 14 | 2026 | 21238 | 0.220 |
Why?
|
| Humans | 35 | 2026 | 131501 | 0.220 |
Why?
|
| No-Reflow Phenomenon | 2 | 2015 | 8 | 0.220 |
Why?
|
| Prospective Studies | 8 | 2025 | 6485 | 0.200 |
Why?
|
| Wearable Electronic Devices | 1 | 2025 | 116 | 0.200 |
Why?
|
| Female | 23 | 2026 | 71086 | 0.200 |
Why?
|
| Anti-Infective Agents | 1 | 2026 | 265 | 0.200 |
Why?
|
| Blood Proteins | 1 | 2024 | 138 | 0.200 |
Why?
|
| Myocytes, Cardiac | 3 | 2020 | 672 | 0.200 |
Why?
|
| Treatment Outcome | 9 | 2026 | 12937 | 0.200 |
Why?
|
| Coronary Vessels | 2 | 2019 | 529 | 0.200 |
Why?
|
| Cardiomegaly | 2 | 2020 | 117 | 0.200 |
Why?
|
| Tuberculosis, Miliary | 1 | 2021 | 10 | 0.180 |
Why?
|
| Interleukin-6 | 1 | 2023 | 417 | 0.170 |
Why?
|
| Prognosis | 4 | 2021 | 4951 | 0.170 |
Why?
|
| Anion Transport Proteins | 1 | 2020 | 31 | 0.170 |
Why?
|
| Monocarboxylic Acid Transporters | 1 | 2020 | 36 | 0.170 |
Why?
|
| Lymphocyte Count | 1 | 2020 | 120 | 0.160 |
Why?
|
| Mitochondrial Membrane Transport Proteins | 1 | 2020 | 59 | 0.160 |
Why?
|
| Prosthesis Design | 2 | 2020 | 610 | 0.160 |
Why?
|
| Echocardiography | 5 | 2019 | 1138 | 0.160 |
Why?
|
| Heart, Artificial | 1 | 2020 | 46 | 0.160 |
Why?
|
| Insulin Receptor Substrate Proteins | 1 | 2020 | 72 | 0.160 |
Why?
|
| Hospital Mortality | 2 | 2026 | 1075 | 0.160 |
Why?
|
| Cardiomyopathy, Hypertrophic | 1 | 2021 | 163 | 0.150 |
Why?
|
| Interferon-gamma | 1 | 2021 | 542 | 0.150 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2021 | 642 | 0.150 |
Why?
|
| Vasodilation | 1 | 2019 | 174 | 0.140 |
Why?
|
| Cardiology | 1 | 2023 | 507 | 0.140 |
Why?
|
| Hematologic Neoplasms | 1 | 2021 | 314 | 0.140 |
Why?
|
| Muscle Proteins | 1 | 2020 | 401 | 0.140 |
Why?
|
| Follow-Up Studies | 6 | 2019 | 5277 | 0.130 |
Why?
|
| Apoptosis | 1 | 2024 | 1861 | 0.130 |
Why?
|
| Excitation Contraction Coupling | 1 | 2017 | 14 | 0.130 |
Why?
|
| Stroke Volume | 5 | 2025 | 529 | 0.130 |
Why?
|
| Microscopy, Confocal | 2 | 2017 | 363 | 0.130 |
Why?
|
| Cardiovascular Agents | 1 | 2017 | 86 | 0.130 |
Why?
|
| Swine | 3 | 2015 | 1187 | 0.130 |
Why?
|
| Atrial Appendage | 1 | 2017 | 76 | 0.120 |
Why?
|
| Endothelium, Vascular | 1 | 2019 | 469 | 0.120 |
Why?
|
| Myocardial Reperfusion | 1 | 2015 | 55 | 0.120 |
Why?
|
| Insulin | 1 | 2020 | 1145 | 0.110 |
Why?
|
| Dabigatran | 1 | 2015 | 26 | 0.110 |
Why?
|
| Arterial Pressure | 1 | 2015 | 131 | 0.110 |
Why?
|
| Predictive Value of Tests | 1 | 2020 | 2297 | 0.110 |
Why?
|
| Intra-Aortic Balloon Pumping | 1 | 2014 | 41 | 0.110 |
Why?
|
| Cell Respiration | 1 | 2014 | 24 | 0.110 |
Why?
|
| Severity of Illness Index | 2 | 2020 | 3089 | 0.110 |
Why?
|
| Mitochondria, Muscle | 1 | 2014 | 36 | 0.110 |
Why?
|
| Thromboembolism | 1 | 2015 | 86 | 0.110 |
Why?
|
| Microscopy, Electron | 1 | 2014 | 314 | 0.110 |
Why?
|
| Anti-Bacterial Agents | 1 | 2026 | 2566 | 0.110 |
Why?
|
| Ubiquitin | 1 | 2014 | 131 | 0.100 |
Why?
|
| Atrophy | 1 | 2014 | 251 | 0.100 |
Why?
|
| Muscle, Smooth | 1 | 2014 | 129 | 0.100 |
Why?
|
| Cardiomyopathy, Dilated | 2 | 2014 | 204 | 0.100 |
Why?
|
| Adult | 8 | 2024 | 31666 | 0.100 |
Why?
|
| Risk Assessment | 2 | 2020 | 3693 | 0.100 |
Why?
|
| Electrocardiography | 2 | 2025 | 983 | 0.100 |
Why?
|
| NG-Nitroarginine Methyl Ester | 1 | 2012 | 57 | 0.100 |
Why?
|
| Diffusion Tensor Imaging | 1 | 2014 | 260 | 0.090 |
Why?
|
| Blotting, Western | 1 | 2014 | 1018 | 0.090 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2014 | 530 | 0.090 |
Why?
|
| Aorta | 1 | 2015 | 529 | 0.090 |
Why?
|
| Heart Failure, Diastolic | 1 | 2012 | 10 | 0.090 |
Why?
|
| Cardiac Surgical Procedures | 1 | 2021 | 1170 | 0.090 |
Why?
|
| Up-Regulation | 1 | 2014 | 832 | 0.090 |
Why?
|
| Hyperparathyroidism, Secondary | 1 | 2012 | 17 | 0.090 |
Why?
|
| DNA Methylation | 1 | 2018 | 1085 | 0.090 |
Why?
|
| Hemangioma, Cavernous, Central Nervous System | 1 | 2011 | 20 | 0.090 |
Why?
|
| Hemorrhage | 1 | 2015 | 498 | 0.090 |
Why?
|
| Blood Flow Velocity | 1 | 2012 | 426 | 0.080 |
Why?
|
| Resistance Training | 1 | 2011 | 26 | 0.080 |
Why?
|
| Osteoporosis | 1 | 2012 | 134 | 0.080 |
Why?
|
| Muscle, Skeletal | 2 | 2014 | 990 | 0.080 |
Why?
|
| Muscle Weakness | 1 | 2011 | 90 | 0.080 |
Why?
|
| Animals | 9 | 2020 | 34335 | 0.080 |
Why?
|
| Heart | 2 | 2016 | 674 | 0.080 |
Why?
|
| Sympathetic Nervous System | 1 | 2010 | 55 | 0.080 |
Why?
|
| Energy Metabolism | 1 | 2014 | 783 | 0.080 |
Why?
|
| Bone Density | 1 | 2012 | 363 | 0.070 |
Why?
|
| Biopsy | 3 | 2019 | 1249 | 0.070 |
Why?
|
| Retrospective Studies | 3 | 2026 | 17648 | 0.070 |
Why?
|
| Heart Rate | 1 | 2011 | 580 | 0.070 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2011 | 588 | 0.070 |
Why?
|
| Models, Genetic | 1 | 2011 | 751 | 0.070 |
Why?
|
| Coronary Artery Disease | 1 | 2015 | 865 | 0.070 |
Why?
|
| Cardiac Catheterization | 2 | 2025 | 635 | 0.070 |
Why?
|
| Risk Factors | 1 | 2020 | 10952 | 0.060 |
Why?
|
| Photoplethysmography | 1 | 2025 | 9 | 0.060 |
Why?
|
| Models, Cardiovascular | 2 | 2018 | 171 | 0.060 |
Why?
|
| Cytokine Receptor gp130 | 1 | 2023 | 12 | 0.050 |
Why?
|
| Adenosine Deaminase | 1 | 2023 | 89 | 0.050 |
Why?
|
| Endothelium | 1 | 2023 | 63 | 0.050 |
Why?
|
| Postoperative Complications | 1 | 2015 | 3113 | 0.050 |
Why?
|
| Mice, Knockout | 2 | 2020 | 3861 | 0.050 |
Why?
|
| Pyrazinamide | 1 | 2021 | 10 | 0.040 |
Why?
|
| Isoniazid | 1 | 2021 | 65 | 0.040 |
Why?
|
| Membrane Potential, Mitochondrial | 1 | 2020 | 46 | 0.040 |
Why?
|
| Absorptiometry, Photon | 2 | 2012 | 199 | 0.040 |
Why?
|
| Pyruvic Acid | 1 | 2020 | 37 | 0.040 |
Why?
|
| Area Under Curve | 1 | 2021 | 320 | 0.040 |
Why?
|
| Exercise Test | 2 | 2011 | 243 | 0.040 |
Why?
|
| Lactic Acid | 1 | 2020 | 144 | 0.040 |
Why?
|
| Oxygen Consumption | 2 | 2012 | 301 | 0.040 |
Why?
|
| Hyperinsulinism | 1 | 2020 | 58 | 0.040 |
Why?
|
| Endothelial Cells | 1 | 2023 | 535 | 0.040 |
Why?
|
| Antitubercular Agents | 1 | 2021 | 264 | 0.040 |
Why?
|
| Societies, Medical | 1 | 2023 | 794 | 0.040 |
Why?
|
| RNA Interference | 1 | 2020 | 496 | 0.040 |
Why?
|
| Registries | 1 | 2026 | 1599 | 0.040 |
Why?
|
| RNA, Small Interfering | 1 | 2020 | 665 | 0.040 |
Why?
|
| Clinical Trials as Topic | 1 | 2023 | 1139 | 0.040 |
Why?
|
| Enhancer of Zeste Homolog 2 Protein | 1 | 2018 | 68 | 0.040 |
Why?
|
| Reactive Oxygen Species | 1 | 2020 | 518 | 0.030 |
Why?
|
| Kruppel-Like Transcription Factors | 1 | 2018 | 112 | 0.030 |
Why?
|
| Periodicity | 1 | 2017 | 49 | 0.030 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2020 | 482 | 0.030 |
Why?
|
| CpG Islands | 1 | 2018 | 337 | 0.030 |
Why?
|
| Case-Control Studies | 2 | 2017 | 3452 | 0.030 |
Why?
|
| Mutation | 1 | 2011 | 6176 | 0.030 |
Why?
|
| Free Radicals | 1 | 2016 | 35 | 0.030 |
Why?
|
| Mice | 3 | 2020 | 18470 | 0.030 |
Why?
|
| Databases, Factual | 1 | 2021 | 1223 | 0.030 |
Why?
|
| Ligation | 1 | 2015 | 136 | 0.030 |
Why?
|
| Sus scrofa | 1 | 2015 | 115 | 0.030 |
Why?
|
| Sequence Analysis, RNA | 1 | 2018 | 420 | 0.030 |
Why?
|
| Mitochondria | 1 | 2020 | 759 | 0.030 |
Why?
|
| Greece | 1 | 2015 | 11 | 0.030 |
Why?
|
| Microcirculation | 1 | 2015 | 111 | 0.030 |
Why?
|
| Insulin Resistance | 1 | 2020 | 678 | 0.030 |
Why?
|
| Recombinant Proteins | 1 | 2018 | 1313 | 0.030 |
Why?
|
| Vascular Resistance | 1 | 2015 | 182 | 0.030 |
Why?
|
| Citrate (si)-Synthase | 1 | 2014 | 17 | 0.030 |
Why?
|
| Ryanodine Receptor Calcium Release Channel | 1 | 2017 | 241 | 0.030 |
Why?
|
| Anisotropy | 1 | 2014 | 124 | 0.030 |
Why?
|
| Electron Transport Complex II | 1 | 2014 | 7 | 0.030 |
Why?
|
| Electron Transport Complex I | 1 | 2014 | 31 | 0.030 |
Why?
|
| Algorithms | 1 | 2021 | 1685 | 0.030 |
Why?
|
| Monte Carlo Method | 1 | 2014 | 102 | 0.030 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2017 | 613 | 0.030 |
Why?
|
| Oxidative Phosphorylation | 1 | 2014 | 129 | 0.030 |
Why?
|
| Cell Line | 1 | 2018 | 2603 | 0.030 |
Why?
|
| Epigenesis, Genetic | 1 | 2018 | 749 | 0.020 |
Why?
|
| Collagen | 1 | 2014 | 289 | 0.020 |
Why?
|
| Phenotype | 2 | 2014 | 4515 | 0.020 |
Why?
|
| Systole | 1 | 2013 | 197 | 0.020 |
Why?
|
| Fibrosis | 1 | 2014 | 412 | 0.020 |
Why?
|
| Rats | 1 | 2018 | 3454 | 0.020 |
Why?
|
| Nuclear Proteins | 1 | 2018 | 1226 | 0.020 |
Why?
|
| Parathyroid Hormone | 1 | 2012 | 76 | 0.020 |
Why?
|
| KRIT1 Protein | 1 | 2011 | 1 | 0.020 |
Why?
|
| Health Status Indicators | 1 | 2012 | 124 | 0.020 |
Why?
|
| Confidence Intervals | 1 | 2012 | 272 | 0.020 |
Why?
|
| Genome, Human | 1 | 2018 | 1332 | 0.020 |
Why?
|
| Computer Simulation | 1 | 2014 | 685 | 0.020 |
Why?
|
| Gene Expression Profiling | 1 | 2018 | 1831 | 0.020 |
Why?
|
| Statistics as Topic | 1 | 2012 | 244 | 0.020 |
Why?
|
| Mice, Inbred C57BL | 1 | 2020 | 4762 | 0.020 |
Why?
|
| Anaerobic Threshold | 1 | 2011 | 11 | 0.020 |
Why?
|
| Statistics, Nonparametric | 1 | 2012 | 432 | 0.020 |
Why?
|
| Loss of Heterozygosity | 1 | 2011 | 124 | 0.020 |
Why?
|
| Muscle Strength | 1 | 2011 | 82 | 0.020 |
Why?
|
| Prostheses and Implants | 1 | 2012 | 143 | 0.020 |
Why?
|
| Apoptosis Regulatory Proteins | 1 | 2011 | 165 | 0.020 |
Why?
|
| Exercise Tolerance | 1 | 2011 | 89 | 0.020 |
Why?
|
| 3-Iodobenzylguanidine | 1 | 2010 | 12 | 0.020 |
Why?
|
| Anticoagulants | 1 | 2015 | 594 | 0.020 |
Why?
|
| Tomography, Emission-Computed | 1 | 2010 | 36 | 0.020 |
Why?
|
| Prosthesis Implantation | 1 | 2011 | 145 | 0.020 |
Why?
|
| Vitamin D | 1 | 2012 | 194 | 0.020 |
Why?
|
| Enzyme Inhibitors | 1 | 2012 | 566 | 0.020 |
Why?
|
| Microtubule-Associated Proteins | 1 | 2011 | 251 | 0.020 |
Why?
|
| Microfilament Proteins | 1 | 2011 | 272 | 0.020 |
Why?
|
| Radiopharmaceuticals | 1 | 2010 | 165 | 0.020 |
Why?
|
| Sodium | 1 | 2010 | 281 | 0.020 |
Why?
|
| Ultrasonography | 1 | 2013 | 972 | 0.020 |
Why?
|
| Body Composition | 1 | 2011 | 550 | 0.020 |
Why?
|
| Creatinine | 1 | 2010 | 399 | 0.020 |
Why?
|
| Young Adult | 2 | 2014 | 10092 | 0.020 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2011 | 600 | 0.020 |
Why?
|
| Natriuretic Peptide, Brain | 1 | 2010 | 326 | 0.020 |
Why?
|
| Incidence | 1 | 2015 | 3344 | 0.020 |
Why?
|
| Gene Expression Regulation, Developmental | 1 | 2011 | 1005 | 0.020 |
Why?
|
| Chronic Disease | 1 | 2011 | 1233 | 0.020 |
Why?
|
| Mice, Transgenic | 1 | 2011 | 2363 | 0.010 |
Why?
|
| Disease Progression | 1 | 2012 | 2205 | 0.010 |
Why?
|
| Genotype | 1 | 2011 | 2655 | 0.010 |
Why?
|
| Disease Models, Animal | 1 | 2015 | 4683 | 0.010 |
Why?
|
| United States | 1 | 2020 | 11794 | 0.010 |
Why?
|
| Exercise | 1 | 2011 | 865 | 0.010 |
Why?
|
| Brain | 1 | 2011 | 3237 | 0.010 |
Why?
|